DK0856520T3 - Fremgangsmåde til fremstilling af et monoklonalt antistof, monoklonalt antistof, et farmaceutisk præparat og et diagnostisk reagens - Google Patents

Fremgangsmåde til fremstilling af et monoklonalt antistof, monoklonalt antistof, et farmaceutisk præparat og et diagnostisk reagens

Info

Publication number
DK0856520T3
DK0856520T3 DK97203769T DK97203769T DK0856520T3 DK 0856520 T3 DK0856520 T3 DK 0856520T3 DK 97203769 T DK97203769 T DK 97203769T DK 97203769 T DK97203769 T DK 97203769T DK 0856520 T3 DK0856520 T3 DK 0856520T3
Authority
DK
Denmark
Prior art keywords
monoclonal antibody
antigens
cells
preparation
pharmaceutical composition
Prior art date
Application number
DK97203769T
Other languages
Danish (da)
English (en)
Inventor
Petrus Gerardus A Steenbakkers
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of DK0856520T3 publication Critical patent/DK0856520T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/04—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers
    • C07K1/042—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length on carriers characterised by the nature of the carrier
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C12N5/163—Animal cells one of the fusion partners being a B or a T lymphocyte
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Analytical Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
DK97203769T 1996-12-06 1997-12-02 Fremgangsmåde til fremstilling af et monoklonalt antistof, monoklonalt antistof, et farmaceutisk præparat og et diagnostisk reagens DK0856520T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP96203465 1996-12-06
EP97201972 1997-06-27

Publications (1)

Publication Number Publication Date
DK0856520T3 true DK0856520T3 (da) 2006-07-31

Family

ID=26143410

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97203769T DK0856520T3 (da) 1996-12-06 1997-12-02 Fremgangsmåde til fremstilling af et monoklonalt antistof, monoklonalt antistof, et farmaceutisk præparat og et diagnostisk reagens

Country Status (17)

Country Link
US (3) US6020170A (pl)
EP (1) EP0856520B1 (pl)
JP (1) JPH10179160A (pl)
KR (1) KR100543053B1 (pl)
AT (1) ATE322507T1 (pl)
AU (1) AU733165B2 (pl)
BR (1) BR9706236A (pl)
CA (1) CA2221682C (pl)
DE (1) DE69735621T2 (pl)
DK (1) DK0856520T3 (pl)
ES (1) ES2262170T3 (pl)
HU (1) HUP9702359A3 (pl)
IL (1) IL122233A (pl)
NO (1) NO327047B1 (pl)
NZ (1) NZ329314A (pl)
PL (1) PL193821B1 (pl)
PT (1) PT856520E (pl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1141026T3 (da) * 1998-12-22 2007-03-26 Raven Biotechnologies Inc Sammensætninger og fremgangsmåder til frembringelse af monoklonale antistoffer repræsentative for en specifik celletype
SE9902817D0 (sv) 1999-07-30 1999-07-30 A & Science Invest Ab A method for selective electrofusion of at least two fusion partners having cell-like membranes
NZ518256A (en) * 1999-10-18 2004-01-30 Akzo Nobel Nv Modified peptides and peptidomimetics for use in immunotherapy
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
WO2002014870A2 (en) 2000-08-14 2002-02-21 Akzo Nobel N.V. Use of antibodies against specific mhc-peptide complexes
PL369010A1 (pl) * 2001-07-24 2005-04-18 Yale University Sposoby, kompozycje i zestawy dotyczące chitynaz i chitynopodobnych cząsteczek oraz choroby zapalnej
US7018819B2 (en) * 2001-11-30 2006-03-28 Cellectricon Ab Method and apparatus for manipulation of cells and cell-like structures focused electric fields in microfludic systems and use thereof
WO2004087911A1 (ja) * 2003-03-28 2004-10-14 Toyama New Industry Organization １個の抗原特異的ｂリンパ球を用いた抗原特異的抗体産生ハイブリドーマの作製方法及びモノクローナル抗体の製造方法
WO2005042743A2 (en) 2003-08-18 2005-05-12 Medimmune, Inc. Humanization of antibodies
US20060228350A1 (en) * 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
EP1729805A4 (en) * 2004-02-25 2008-11-26 Medimmune Inc METHODS AND COMPOSITIONS RELATED TO CHITINASES AND CHITINASE-MOLECULARS AND MODULATION OF OSTEOCLASTS
JP2008528010A (ja) * 2005-01-31 2008-07-31 アブリンクス ナームローゼ フェンノートシャップ 重鎖抗体の可変ドメイン配列を作出する方法
AU2006227377B2 (en) 2005-03-18 2013-01-31 Medimmune, Llc Framework-shuffling of antibodies
CA2613512A1 (en) 2005-06-23 2007-01-04 Medimmune, Inc. Antibody formulations having optimized aggregation and fragmentation profiles
US20070071746A1 (en) * 2005-08-31 2007-03-29 Medimmune, Inc. C/CLP antagonists and methods of use thereof
EP3363415B1 (en) * 2008-01-09 2019-10-02 Alcon Lensx, Inc. Curved photodisruptive laser fragmentation of tissue
US20160075766A1 (en) * 2013-05-21 2016-03-17 Roche Diagnostics Operations, Inc. Method for producing antibodies using ovine b-cells and uses thereof
EP3717632B1 (en) 2017-11-30 2022-10-26 F. Hoffmann-La Roche AG B-cell cultivation method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4550086A (en) * 1983-02-16 1985-10-29 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies that recognize human T cells
EP0255547A1 (en) * 1986-07-29 1988-02-10 Kishimoto, Tadamitsu, Prof. Monoclonal antibodies specific to surface receptor for IgE and hybrid cell lines producing these antibodies and use thereof
US5766947A (en) * 1988-12-14 1998-06-16 Astra Ab Monoclonal antibodies reactive with an epitope of a Vβ3.1 variable region of a T cell receptor
US5223426A (en) * 1988-12-15 1993-06-29 T Cell Sciences, Inc. Monoclonal antibodies reactive with defined regions of the t-cell antigen receptor
US5162223A (en) * 1989-02-17 1992-11-10 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Resources Hybridomas and resulting monoclonal antibodies directed against antigens of Bordetella pertussis
US5473051A (en) * 1990-07-19 1995-12-05 The Scripps Research Institute Inhibition of Mac-1 receptor binding to fibrinogen using D30 homologs
ZA919299B (en) * 1990-11-26 1992-08-26 Akzo Nv Method for the production of antibodies
AU729406B2 (en) * 1996-03-28 2001-02-01 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins

Also Published As

Publication number Publication date
MX9709446A (es) 1998-07-31
NO327047B1 (no) 2009-04-14
PT856520E (pt) 2006-08-31
HUP9702359A2 (hu) 1998-09-28
NO975714L (no) 1998-06-08
HUP9702359A3 (en) 2001-11-28
EP0856520A1 (en) 1998-08-05
NO975714D0 (no) 1997-12-05
KR19980063909A (ko) 1998-10-07
DE69735621T2 (de) 2006-08-24
ATE322507T1 (de) 2006-04-15
HU9702359D0 (en) 1998-03-02
CA2221682A1 (en) 1998-06-06
BR9706236A (pt) 1999-05-04
ES2262170T3 (es) 2006-11-16
PL323572A1 (en) 1998-06-08
DE69735621D1 (de) 2006-05-18
PL193821B1 (pl) 2007-03-30
IL122233A (en) 2001-04-30
KR100543053B1 (ko) 2006-06-13
NZ329314A (en) 1999-02-25
CA2221682C (en) 2011-10-18
AU733165B2 (en) 2001-05-10
US20020143150A1 (en) 2002-10-03
US6020170A (en) 2000-02-01
AU4690897A (en) 1998-06-11
US6392020B1 (en) 2002-05-21
IL122233A0 (en) 1998-04-05
JPH10179160A (ja) 1998-07-07
EP0856520B1 (en) 2006-04-05

Similar Documents

Publication Publication Date Title
DK0856520T3 (da) Fremgangsmåde til fremstilling af et monoklonalt antistof, monoklonalt antistof, et farmaceutisk præparat og et diagnostisk reagens
DK0699755T3 (da) Fremgangsmåde til opnåelse af modificerede immunglobuliner med reduceret immunogenicitet af variable domæner i et murint antistof, præparater der indeholder disse
DK1414858T3 (da) Kamelid-enkeltkæde-VHH-antistoffer, fremgangsmåde til fremstilling heraf i et pattedyr samt anvendelser heraf
DK0885614T3 (da) Fremgangsmåde til ex vivo-immunisering ved hjælp af heterologe intakte divalente og/eller trivalente antistoffer
DK0458841T3 (da) Fremgangsmåde til anvendelse og fremstilling af peptider
FI100973B (fi) Menetelmä antigeenirakenteiden valmistamiseksi "Major Histocompatibili ty Complex" (MHC) luokka I -antigeeneistä ja monoklonaalisista vasta-a ineista
DE69632667D1 (de) CTLA4-Mutantmoleküle und deren Verwendung
DE69133179D1 (de) Katalytische antikörperkomponente
ES2159681T3 (es) Ensayo de aglutinacion en columnas y dispositivo.
ATE200679T1 (de) Neues verfahren zur herstellung von anti-humanen antigenrezeptoren und deren verwendungen
ES2165851T3 (es) Proteinas multivalentes que se unen a antigenos.
DK121683D0 (da) Fremgangsmade til fremstilling af immunoenzymatiske konjugater
CA2095735A1 (en) Monoclonal antibodies to hepatitis c virus and method for using same
DE69020914D1 (de) Monoklonale Antikörper von Ratten gegen menschliche Antigene und Verfahren zu deren Herstellung.
ES2060927T3 (es) Anticuerpos contra la fibrina; peptidos inmunogenos adecuados para preparar los anticuerpos, metodo para determinar fibrina y preparacion farmaceutica basada en los anticuerpos.
EP0889054A3 (de) Antikörper 67D2 gegen CD164
DK0476059T3 (da) Fremgangsmåder til forøgelse af modificeringshastigheden for metastabile bindinger
EP0338497A3 (en) Bispecific hybrid monoclonal antibody
PT93394A (pt) Processo para a preparacao de celulas de hibridonas produzindo anticorpos ligaveis a moleculas de adesao intercelular